Silo pharma secures exclusive global license for alzheimer's therapeutic

Agreement enhances company's intellectual property portfolio sarasota, fl, july 16, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its alzheimer's drug spc-14. silo intends to utilize the fda's streamlined 505(b)(2) pathway for spc-14, which would shorten clinical timelines and reduce drug development costs.
SILO Ratings Summary
SILO Quant Ranking